Function of Inflammation Factors in Aflibercept or Ranibizumab Treatment on Alleviating Wet Age-related Macular Degeneration

Status

Active, not recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1800017782

Enrollment

Unknown

Registered

2018-08-14

Start date

2015-05-04

Completion date

Unknown

Last updated

2018-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Wet Age-related Macular Degeneration

Interventions

Group 1:Ranibizumab

Group 2:Aflibercept

Eligibility

Sex/Gender

All

Age

47 Years to 67 Years

Inclusion criteria

Inclusion criteria: Wet AMD patients enrolled should have primary or recurrent CNV associated with wet AMD.

Exclusion criteria

Exclusion criteria: None of the recruited patient had received anti-VEGF treatment before one year from this study. However, subjects with hyperlipidaemia, hypertension, diabetes mellitus, heart failure and renal failure were excluded.

Design outcomes

Primary

Measure	Time frame
visual acuity letter score;central subfield thickness;	—

Countries

China

Contacts

Public ContactJianshu Yuan

Ningbo 6th Hospital

Jianshu_Yuan6407@163.com+86 0574 87801999

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 21, 2026